Halegoua-DeMarzio Dina, Navarro Victor J, Davis Ashley, Ahmad Jawad, Avula Bharathi, Barnhart Huiman, Barritt A Sidney, Bonkovsky Herbert L, Chen Vincent L, Choi Gina, Fontana Robert J, Ghabril Marwan S, Khan Ikhlas, Koh Christopher, Odin Joseph, Rockey Don C, Rostami Hoss, Serrano Jose, Sherker Averell H, Stolz Andrew, Tillmann Hans L, Vuppalanchi Raj
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Jefferson-Einstein Medical Center, Philadelphia, PA, USA.
Drug Saf. 2025 Feb;48(2):143-150. doi: 10.1007/s40264-024-01484-8. Epub 2024 Oct 1.
The attribution of drug-induced liver injury (DILI) to specific herbal and dietary supplements (HDS) is confounded by inaccurate labels and undisclosed ingredients. The US Drug-Induced Liver Injury Network (DILIN) determines the attribution of injury to an agent through its structured expert opinion causality assessment process, but without the use of chemical analysis data of HDS. We aimed to determine the impact of chemical analysis of HDS products on prior causality assessment scores.
Obtained samples of HDS consumed by DILIN-enrolled patients were analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). Chemical analysis data were compared to label accuracy and detect whether the product contained botanical and non-botanical compounds. A comparison of the causality scores reassessed with chemical analysis was compared with the original scores.
A total of 54 previously adjudicated cases with chemical analysis available were reassessed for causality with chemical analysis data; reviewers were blinded to original causality scores. Using the chemical analysis data, 37% (n = 20) of the 54 cases were scored with a higher likelihood of DILI compared with the original causality scores; 14 of the 20 (70%) moved from probable to highly likely; 52% had no change in causality score; and 11% of cases were scored as a lower likelihood of DILI.
Our study demonstrates that there is value in using HDS chemical analysis data in the causality assessment process for DILI. In more than a third of cases, chemical analysis of products led to an increased confidence in DILI attribution to HDS. These findings suggest that chemical analysis is an important tool in causality assessment for HDS agents, specifically in challenging situations, and further studies are needed to confirm its applicability in clinical practice.
药物性肝损伤(DILI)归因于特定草药和膳食补充剂(HDS)时,会因标签不准确和成分未公开而受到干扰。美国药物性肝损伤网络(DILIN)通过其结构化的专家意见因果关系评估过程来确定损伤对某种药物的归因,但未使用HDS的化学分析数据。我们旨在确定HDS产品的化学分析对先前因果关系评估分数的影响。
对DILIN登记患者所服用的HDS样本进行高效液相色谱 - 质谱联用(HPLC - MS)分析。将化学分析数据与标签准确性进行比较,并检测产品是否含有植物性和非植物性化合物。将根据化学分析重新评估的因果关系分数与原始分数进行比较。
共有54例先前已判定且有化学分析数据的病例,利用化学分析数据重新评估其因果关系;评估人员对原始因果关系分数不知情。根据化学分析数据,54例病例中有37%(n = 20)的DILI可能性评分高于原始因果关系分数;20例中的14例(70%)从“可能”变为“极有可能”;52%的病例因果关系分数无变化;11%的病例DILI可能性评分降低。
我们的研究表明,在DILI因果关系评估过程中使用HDS化学分析数据是有价值的。在超过三分之一的病例中,产品的化学分析使对HDS导致DILI的归因更有信心。这些发现表明,化学分析是HDS药物因果关系评估的重要工具,特别是在具有挑战性的情况下,还需要进一步研究以确认其在临床实践中的适用性。